Dark

Check out our Level2View

NRSN
NeuroSense Therapeutics Ltd.
stock NASDAQ

At Close

May 8, 2025 3:59:30 PM EDT

1.05USD+3.164%(+0.03)69,105

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 7, 2025 9:08:30 AM EDT

1.02USD+0.226%(+0.00)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

09:03AM EST NeuroSense Therapeutics to Present at BIO CEO & Investor Conference PR Newswire

Jan 27, 2022

08:37AM EST NeuroSense Therapeutics Extends ALS Biomarker Collaboration With Massachusetts General Hospital Benzinga

08:31AM EST NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts PR Newswire

Jan 7, 2022

01:07PM EST Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 Benzinga

01:05PM EST Maxim Group Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $7 Benzinga

Jan 4, 2022

09:24AM EST NeuroSense Therapeutics, Ltd. Announces Presentation Of Phase IIa Study Results At Four International Conferences Benzinga

09:24AM EST NeuroSense Therapeutics, Ltd. Announces the Presentation of Phase IIa Study PR Newswire

Dec 21, 2021

09:03AM EST NeuroSense Therapeutics Ltd. Expands Board of Directors and Adds Chief Medical PR Newswire

Dec 15, 2021

12:21PM EST Neurosense Therapeutics European Patent Register Shows Abstract For Co.'s 'COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY DRUG AND A DICER ACTIVATOR FOR USE IN THE TREATMENT OF NEURONAL DISEASES' Benzinga

Dec 13, 2021

04:01PM EST NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq PR Newswire

Dec 12, 2021

04:56PM EST The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More Benzinga

Dec 9, 2021

09:52PM EST NeuroSense Therapeutics Shares Earlier Opened For Trade At $4.55; IPO Priced $6/Share Benzinga

09:46PM EST The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO Benzinga

Share